Precision Medicine in Urothelial Carcinoma Using Patient-Derived Organoids and Microfluidic Chips

Overview

This study aims to improve cancer treatment by using patient-derived tumor organoids. Traditional two-dimensional cell models cannot fully represent the real tumor environment, so drug testing results are often inaccurate. In this study, tumor tissues from patients with urothelial carcinoma were used to grow three-dimensional organoids that closely resemble the original tumors. These organoids were then treated with several common chemotherapy drugs to evaluate differences in drug responses between patients. In addition, microfluidic chip technology was used to create a more realistic and dynamic culture environment. The results showed that tumor organoids preserved tumor characteristics and displayed different drug sensitivities. This approach may help doctors choose more effective and personalized treatments in the future.

Awards (2)

• Silver Medal
• Selected for CWSF 2026

Competition history

• CWSF 2026 Disease & Illness

Related projects

Closest projects by meaning, across every fair and year in the corpus.